Ad
Wednesday, 27 June 2018
AstraZeneca, Merck eye $1 billion boost from cancer drug success
LONDON (Reuters) - AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment